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Abstract
Aims To describe the safety and performance of STENTYS self-expandable bare metal stents (BMS) versus paclitaxel-
eluting stents (PES) in saphenous vein grafts (SVGs).
Methods and Results A randomised controlled trial was performed in four hospitals in three European countries between
December 2011 and December 2013. Patients with de novo lesions (>50% stenosis) in an SVG with a diameter between
2.5–6 mm were included. Primary endpoint was late lumen loss at 6 months. Secondary endpoints included procedural
success and the occurrence of major adverse cardiac events (MACE) at 12 months. A total of 57 patients were randomised
to STENTYS self-apposing BMS (n = 27) or PES (n = 30). Procedural success was obtained in 89.5%. No significant
differences in late lumen loss were found between BMS and PES at 6 months (0.53 mm vs 0.47; p = 0.86). MACE rates
at 12 months were comparable in both groups (BMS 22.2% vs. PES 26.7%; p = 0.70).
Conclusions Treatment of SVGs with STENTYS self-expandable stents is safe and effective. No significant differences
were found in late lumen loss and MACE between BMS and PES.
Keywords Percutaneous coronary intervention · Drug-eluting stent · Bare metal stent · Self-apposing stent · Saphenous
vein grafts
Introduction
Saphenous vein grafts (SVGs) can occlude over time be-
cause of thrombosis, intimal hyperplasia and atherosclero-
sis. Occlusions of SVGs are reported in 10–15% of patients
within 1 year after coronary artery bypass grafting (CABG)
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surgery and after 10 years almost half of the SVGs fail [1].
Currently 10% of the patients being treated in a high-vol-
ume catheterisation lab are patients who need treatment
of their occluded SVGs [2]. These patients can encounter
complications such as embolisation, peri-procedural my-
ocardial infarction (MI), increased incidence of resteno-
sis, repeat percutaneous coronary intervention (PCI) and
a faster progression of moderate ‘non-significant’ lesions,
treated during the first intervention [3, 4]. Originally SVGs
were treated with balloon angioplasty alone. Subsequently
the SAVED trial showed beneficial procedural results and
a decrease in major adverse cardiac events (MACE) with
the use of bare metal stents (BMS) compared with balloon
angioplasty [5].
Since the introduction of drug-eluting stents (DES) at
least two meta-analyses have reported lower MACE and
repeat revascularisation rates with DES but, overall, similar
mortality rates [6, 7]. However, the majority of the articles
in the meta-analyses were observational studies. Recently
a meta-analysis with only four randomised controlled trials
showed that the use of DES in SVGs was associated with
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a significant reduction in risk of repeat revascularisation. In
addition, there were no differences in the incidence of all-
cause death and nonfatal MI between DES and BMS [8].
Besides a lack of methodological evidence (randomised
controlled trials, RCTs) in the assessment of PCI treatment
of SVGs, there is also limited information about the role of
self-expandable stents. The implantation of self-expandable
stents in SVGs has theoretical advantages compared with
balloon-expandable stents, such as less risk of undersizing
or oversizing in a vessel with a large lumen diameter and
calibre change, especially at the anastomosis site. Secondly,
deployment could limit the risk of distal embolisation as it
is deployed in a distal to proximal direction. Third, the
self-expanding mechanism could improve apposition after
thrombus resolution following PCI. The Symbiot III study,
a randomised trial with 400 patients, compared BMS with
a self-expanding polytetrafluoroethylene covered stent in
the treatment of de novo and restenotic SVG lesions. No
differences were reported in the MACE rate at 8 months
or in angiographic restenosis [9]. As discussed before, the
optimal treatment (BMS or DES) in SVGs has yet not been
established.
For this reason, a randomised study, systematically com-
paring the safety and efficacy of a self-expanding BMS with
a self-expanding DES in SVGs, may provide meaningful
results and lead to improved treatment of SVGs.
Methods
Patient population
Patients were eligible if they were at least 18 years of
age and were willing to comply with the follow-up eval-
uations. Angiographic eligibility criteria were de novo le-
sions (>50% stenosis) in SVGs with a diameter between
2.5–6 mm by visual estimation. Finally, patients had to un-
derstand the nature of the procedure and provide written
informed consent prior to the procedure. The following
exclusion criteria were applied: patients with cardiogenic
shock, any vasculature lesions or characteristics preventing
the safe performance of a PCI with the STENTYS deliv-
ery system or placement of the STENTYS stent, allergies
or contraindications to antiplatelet medication, known al-
lergies to stent components and female patients with child
bearing potential not taking adequate contraceptives or cur-
rently breastfeeding.
Study personnel approached the patients who met the
inclusion criteria. Patients were told that even if they were
willing to participate in the study, further examinations
might demonstrate that they were not suitable. Written in-
formed consent was obtained from all patients. The study
complied with the Declaration of Helsinki and was ap-
Fig. 1 The STENTYS stent is deployed by retracting an outer sheath
which releases the stent from the distal edge
proved by the Ethics Committees of the sites before study
enrolment commenced.
Study design and procedures
Patients were included at four medical centres in Europe
(Albert Schweitzer Hospital, Dordrecht, the Netherlands;
Onze Lieve Vrouwe Gasthuis, Amsterdam, the Nether-
lands; ZNA Middelheim, Antwerpen, Belgium; and Sa-
takunta Hospital, Pori, Finland). Eligible patients were
consecutively randomised to treatment with a STENTYS
BMS or a STENTYS paclitaxel-eluting stent (PES). The
allocation schedule was based on computer-generated ran-
dom numbers on a 1:1 basis. The study was conducted on
the STENTYS self-expanding PES or BMS, which feature
small interconnections that can be disconnected by inflat-
ing a balloon catheter to provide access to the side branch
and full ostium coverage[10]. The concept of the device is
shown in Fig. 1. Self-expanding stents have been proven to
be safe and effective in the treatment of patients with coro-
nary bifurcation lesions[11] and STEMI patients[12]. Both
stents were self-expanding with a nickel titanium alloy
(nitinol) on a rapid exchange delivery system. The stents
were available in diameters of 2.5–4.5 mm and in lengths of
17–27 mm. Balloon angioplasty and coronary stent implan-
tation were performed using standard techniques. The use
of a filter-wire or any other distal protection was encour-
aged but the final decision was at the operator’s discretion.
Pre- and post-dilatation were recommended, although left
to the discretion of the operator. All patients were treated
with at least 80 mg acetylsalicylic acid and 300–600 mg
clopidogrel before or at the time of the procedure. During
PCI, unfractionated heparin in a dose of at least 100 IU/kg
was administered to maintain an activated clotting time
>200 s. The use of glycoprotein IIb/IIIa antagonists was
left to the discretion of the operator. All patients were
asked to return for angiographic follow-up at 6 months
(±30 days).
Quantitative coronary angiography
Coronary angiograms were digitally recorded at baseline
and at 6 months (±30 days) follow-up. An independent
core lab assessed the images (Diagram BV, Zwolle, the
Netherlands). The projections that best showed the steno-
sis were used for analysis. Quantitative measurements in-
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cluded the diameter of the vessel, the minimal luminal di-
ameter (MLD), percent diameter stenosis, and late lumen
loss which was defined as the difference between MLD
after the procedure and MLD at follow-up. Binary steno-
sis was defined as stenosis of 50% or greater of the MLD
in the target lesion at angiographic follow-up. All angio-
graphic measurements of the target lesion were obtained
in the stented area, within the margins 5 mm proximal and
distal to each stent edge.
Cardiac clinical outcomes
The primary endpoint of this study was in-stent late lumen
loss at 6-month follow-up, assessed by quantitative coro-
nary angiography (QCA). The main secondary endpoints
were: procedural success (defined as attainment of <30%
final residual stenosis and no periprocedural complications),
major adverse cardiac events at 12 months (MACE; defined
as cardiac death, MI, emergent CABG or clinically driven
target lesion revascularisation), target vessel failure (TVF;
defined as cardiac death, target vessel myocardial infarc-
tion or clinically driven target vessel revascularisation) at
12 months, binary restenosis at 6 months and stent strut
malapposition at 6 months.
Sample size
The primary measure of patient outcome was in-stent late
lumen loss at 6-month follow-up. To show a difference
between the mean per-lesion in-stent late lumen loss in
the STENTYS BMS group (estimated lumen loss: 1.0 ±
0.9 mm) and the STENTYS PES group (estimated lumen
loss: 0.5 ± 0.7 mm), 40 analysable patients needed to be
enrolled in both groups, assuming a 1:1 patient allocation
ratio of the treatments and a type I error (α) of 0.05 (two-
sided). However, because enrolment was slower than an-
ticipated, 57 patients were randomised (27 patients to the
STENTYS BMS stent and 30 patients to the STENTYS
PES stent).
Statistical analysis
The primary analysis sample was based on the principle of
intention-to-treat using SPSS (SPSS Inc., Chicago, Illinois).
In the intention-to-treat population, all patients who gave
informed consent and were randomised were included in
the analysis sample, regardless of whether or not the treat-
ment device was successfully implanted. The per-protocol
population were the population who fulfilled the inclusion
and exclusion criteria, who received the treatment device
they were randomised to and who completed the 6-month
follow-up. The primary endpoint is the in-stent late lumen
loss at 6 months of follow-up; means and standard devi-
ations per treatment group were reported. Student’s t-test
for independent groups was used to test for statistical sig-
nificance of the primary endpoint. The test is two-sided
and an alpha of 5% was used as the level of significance.
Levene’s test for equality of variances was conducted and
if necessary, a modified t-test that does not assume equality
of variance was used. We checked for normality of in-stent
late lumen loss scores by means of visual examination. If
necessary these scores were transformed to obtain a normal
distribution. For secondary outcomes, standard Chi-square
tests was performed to compare percentages of categorical
data. In case of rare events (the expected number per cell
lower than 5 in more than 20% of the cells) the Fisher’s ex-
act test was used. For ordinal categorical data a chi-square
test for linear trend was performed. Depending on the dis-
tribution of the data, T-tests or Mann-Whitney U tests were
used for continuous data. All tests are two-sided and an
alpha of 5% was used as the level of significance.
Results
Baseline and procedural characteristics
Between December 2011 and December 2013, 57 patients
were consecutively enrolled in the ADEPT trial and were
randomised to BMS (n = 27) or PES (n = 30) (Fig. 2).
Baseline and procedural characteristics were not statisti-
cally different in both groups (Tab. 1).
Most of the treated patients were men (87.7%). The mean
age of the population was 73.4 ± 8.9 years. Most PCI in-
dications for SVG treatment were stable angina (43.9%)
and unstable angina (40.4%). The mean graft age was 16.2
years. Embolic protection was used in 10 (17.5%) lesions;
no distal embolisation was reported. Procedural success was
achieved in 51 (89.5%) patients.
Primary endpoints
Angiographic follow-up was completed according to pro-
tocol, 6 months after stent implantation, in 40 of the
57 patients (70.1%). The follow-up angiographic results
are presented in Tab. 2. No significant differences in late
lumen loss were found between the BMS and PES group:
0.53 mm ± 1.09 and 0.47 mm ± 0.95 respectively (p =
0.86).
Secondary endpoints
The clinical outcomes up to 1-year of follow-up are pre-
sented in Tab. 3. During follow-up to 365 days, 14 of 57 pa-
tients experienced at least 1 MACE: 6 of 27 BMS patients
and 8 of 30 PES patients (p = 0.70). There were also no
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Fig. 2 Study flow chart. Allo-
cation, follow-up and analysis.
Lost to follow-up: if the pa-
tient missed two consecutive
scheduled contact time points
and attempts at communicating
with the patient were unsuccess-
ful, the patient was considered
lost-to-follow-up. (ITT analy-
sis Intention-to-treat analysis;
all patients who gave informed
consent and were randomised,
PP analysis Per-protocol anal-
ysis; the patients who fulfil the
inclusion and exclusion criteria,
who have received the treatment
device they were randomised
to and who have completed the
6-month follow-up)
Allocated to bare metal stent
(n=27)
Analysis at 12 months
ITT analysis (n=27)
PP analysis (n=15)
Excluded from PP analysis (n=12)
φ Visit outside time window (n=1)
φ No 6-month follow-up angiogram (n=11)
Angiographic follow-up at 6 months: (n=16)
Lost to follow-up ( n=8 )
φ Death ( n=3 )
Angiographic follow-up at 6 months: (n=20)
Lost to follow-up (n=8)
φ Death ( n=2)
Allocated to paclitaxel-eluting stent
(n=30)
Analysis at 12 months
ITT analysis (n=30)
PP analysis (n=18)
Excluded from PP analysis (n=14)
φNo de novo lesion (n=1)
φ Visit outside time window (n=3)
φNo 6-month follow-up angiogram (n=10)
Allocation
Analysis
Follow-up
Randomised (n=57)
significant differences in TVF rates between both groups
(BMS group 22.1%; PES group 20.0%; p = 0.84). Five
of the 57 patients died during follow-up: 3 patients in the
BMS and 2 in the PES group. The 2 patients who died in
the PES group were non-cardiac deaths (1 due to urosepsis
and 1 due to urothelial cell carcinoma). The 3 patients in
the BMS group were cardiac deaths (1 sudden death and
2 with unknown cardiac cause). Six of the 57 patients ex-
perienced an MI (1 in the BMS and 5 in PES group; p =
0.20) during follow-up. Target vessel revascularisation was
reported in 3 of the 6 MI patients: 1 in the BMS group
(NSTEMI) and 2 in the PES group (1 acute in-stent throm-
bosis within 30 days, and 1 in-stent restenosis and in-stent
thrombosis within 180 days). The other 3 patients with MI
were related to non-target vessels. Clinically driven target
lesion revascularisation was necessary in 9 of the 57 pa-
tients (4 in BMS and 5 in PES; p = 0.99). Binary restenosis
at 6 months was reported in 5 of 40 patients, including 3 in
the BMS group and 2 in the PES group (p = 0.64).
Discussion
STENTYS self-expandable stents have the unique feature
of positive adaptation to the vessel size. When adrenergic
activation leading to vasoconstriction diminishes in the days
after PCI, and dual antiplatelet medication starts to dissolve
the encaged thrombus, a stent self-expanding to an optimal
size and apposition may have additional benefits [13].
Especially in SVGs, with a larger vessel size than a na-
tive coronary artery, the risk of undersizing is reduced by
the STENTYS self-expandable stents. Furthermore, the po-
tential for distal embolisation could be reduced as the stent
deploys in a distal to proximal direction; in the current study
no distal embolisation was reported. Finally, vessel wall in-
jury, which has a direct relation with neo-intimal prolifer-
ation, might be limited by self-expanding stents compared
with balloon-expanding stents, which is important in this
high-risk population [14]. The main findings of our study
suggest that the implantation of STENTYS self-expand-
able stents is safe and effective in the treatment of SVGs.
No significant differences were found in angiographic and
clinical parameters, such as late lumen loss, MACE and
TVF between STENTYS BMS and STENTYS PES during
the follow-up period.
A recent meta-analysis was performed comparing BMS
versus DES in SVG lesions [8]. This meta-analysis com-
pared the results of four other randomised controlled trials
(RCTs): the ISAR-CABG [15], SOS; [16, 17], BASKET
[18] and RRISC [19, 20]. The characteristics of these four
trials are summarised in Tab. 4. Some differences between
the ADEPT trial and the other RCTs are noteworthy. First,
the number of patients included in the ADEPT is relatively
small compared with the ISAR-CABG with 610 partici-
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Table 1 Baseline and procedural characteristics of the study population
BMS (n = 27) PES (n = 30) All (n = 57) P Value
Age (years) 73.3 ± 7.9 73.5 ± 9.8 73.4 ± 8.9 0.92
Male gender 25 (92.6%) 25 (83.3%) 50 (87.7%) 0.43
Age graft (years) 15.9 ± 8.7 16.5 ± 7.7 16.2 ± 8.1 0.77
Cardiac risk factors
Diabetes mellitus 9 (33.3%) 10 (33.3%) 19 (33.3%) 0.99
Hypertension 15 (55.6%) 20 (66.7%) 35 (61.4%) 0.39
Hypercholesterolaemia 15 (55.6%) 19 (63.3%) 34 (59.6%) 0.55
Current smoking 3 (11.1%) 5 (16.7%) 8 (14.0%) 0.71
Family history of CAD 9 (33.3%) 14 (46.7%) 23 (40.4%) 0.59
Past medical history
Myocardial infarction 12 (44.4%) 15 (50.0%) 27 (47.4%) 0.59
Previous PCI 13 (48.1%) 15 (50.0%) 28 (49.1%) 0.89
Previous CABG 27 (100.0%) 30 (100.0%) 57 (100%) 0.99
Previous stroke 0 (0%) 4 (13.3%) 4 (7.0%) 0.11
Indication for PCI
Stable angina 11 (40.7%) 14 (46.7%) 25 (43.9%) 0.65
Unstable angina 12 (44.4%) 11 (36.7%) 23 (40.4%) 0.55
Silent ischaemia 1 (3.7%) 2 (6.7%) 3 (5.3%) 0.99
Other 3 (11.1%) 3 (10.1%) 0.99
Number of stents used at target lesion
1 26 (96.3%) 30 (100%) 56 (98.2%) 0.47
2 6 (22.2%) 5 (16.7%) 11 (19.3%) 0.60
3 1 (3.7%) 2a (6.7%) 3 (5.3%) 0.99
QCA Pre-procedural results
Lesion length, mean (mm) 15.92 ± 7.34 16.92 ± 7.89 16.44 ± 7.57 0.59
Reference diameter (mm) 3.11 ± 0.84 3.26 ± 0.58 3.19 ± 0.71 0.96
Minimal lumen diameter (mm) 1.36 ± 0.64 1.34 ± 0.56 1.35 ± 0.59 0.92
Stenosis, % lumen diameter 55.02 ± 19.52 58.00 ± 17.98 56.56 ± 18.63 0.49
Embolic protection device use 4 (14.8%) 6 (20%) 10 (17.5%) 0.73
Success rates
Device success 26 (96.3%) 28 (93.3%) 54 (94.7%) 0.99
Procedure success 25 (92.6%) 26 (86.7%) 51 (89.5%) 0.67
Clinical success 25 (92.6%) 26 (86.7%) 51 (89.5%) 0.67
Values are mean ± SD or n (%)
BMS bare-metal stent(s), PES paclitaxel-eluting stent(s), CAD coronary artery disease, PCI percutaneous coronary intervention, CABG coronary
artery bypass graft, SVG saphenous vein grafts, QCA quantitative coronary angiography
aDifferent stent types were implanted (non-STENTYS stent)
pants, although other trials show a similar population size
[15]. The BASKET trial [18], with 47 participants, is the
only trial that enrolled less patients than ADEPT. The other
two RCTs enrolled 80 [16, 17] and 75 [19, 20] participants,
respectively. A notable baseline difference is the mean age
of the treated SVGs. In the ADEPT trial, the mean age of
the graft was 16.2 years, which seems significantly older
than in the other studies, where the age of the graft varies
between 11 and 13.8 years [8]. Other baseline character-
istics, such as cardiac risk factors, are similar to the other
RCTs. The 12-month follow-up time of the ADEPT trial is
the same as the ISAR-CABG trial, although shorter than the
other three RCTs, which varied between 18 and 36 months.
Also, less patients returned for follow-up angiography at
6 months compared with the other trials. This was despite
multiple attempts by the study personnel to contact the pa-
tients.
To place these data in the context of previous trials is
challenging. When comparing late lumen loss at 6 months
between the STENTYS self-expanding BMS (0.53 mm ±
1.09 mm) and STENTYS self-expanding PES (0.47 mm ±
0.95 mm), the data seem consistent with results in native
coronary vessels and from similar studies of SVGs [8].
The paclitaxel-eluting version did not show improved
angiographic follow-up results, while in the four historical
randomised trials a difference in QCA outcomes in favour
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Table 2 Lumen area development‡
BMS (n = 27) PES (n = 30) All (n = 57) P value
Diameter stenosis (%)
Pre procedural 55.02 ± 19.52 58.00 ± 17.98 56.56 ± 18.63 0.49
Post procedural 8.08 ± 11.48 7.07 ± 13.89 7.54 ± 12.72 0.97
6 months FU 23.72 ± 32.30 21.25 ± 30.18 22.36 ± 30.77 0.84
RVD (mm)
Pre procedural 3.11 ± 0.84 3.26 ± 0.58 3.19 ± 0.71 0.97
Post procedural 3.22 ± 0.51 3.17 ± 0.53 3.19 ± 0.52 0.97
6 months FU 3.30 ± 0.60 3.11 ± 0.53 3.19 ± 0.56 0.47
MLD (mm)
Pre procedural 1.36 ± 0.64 1.34 ± 0.56 1.35 ± 0.59 0.92
Post procedural 2.93 ± 0.50 2.91 ± 0.47 2.92 ± 0.48 0.94
6 months FU 2.47 ± 1.07 2.43 ± 0.98 2.45 ± 1.01 >0.90
LLL after 6 months (mm) 0.53 ± 1.09 0.47 ± 0.95 0.50 ± 1.00 0.86
Binary restenosis at 6 months (>50%) 3/18 (16.7%) 2/22 (9.1%) 5/40 (12.5%) 0.64
RVD reference vessel diameter, MLD minimal lumen diameter, LLL late lumen loss
Values are mean ± SD or n (%). ‡ In 1 patient a QCA preanalysis was not possible because the catheter tip was not filmed
The numbers of patients returning for angiographic 6 months follow-up: BMS (n = 16), PES (n = 20), All (n = 36)
Table 3 Clinical outcomes during follow-up
BMS (n = 27) PES (n = 30) All (n = 57) P Value
MACE rate
In hospital MACE 0 (0%) 0 (0%) 0 (0%) 0.99
MACE within 30 days 1 (3.7%) 2 (6.7%) 3 (5.3) 0.99
MACE within 180 days 3 (11.1%) 5 (16.7%) 8 (14.0) 0.71
MACE within 365 days 6 (22.2%) 8 (26.6%) 14 (24.6) 0.70
TVF rate
TVF within 365 days 6 (22.2%) 6 (20.0) 12 (21.1) 0.84
Death, any cause 3 (11.1%) 2 (6.7%) 5 (8.8%) 0.66
Cardiac Death 3 (11.1%) 0 (0%) 3 (5.7%) 0.10
MI, any 1 (3.7%) 5 (16.7%) 6 (10.5%) 0.20
Clinical driven TLR 4 (14.8%) 5 (16.7%) 9 (15.8%) 0.99
MACE major adverse cardiac events, MI myocardial infarction, TLR target lesion revascularisation
Values are mean ± SD or n (%)
of DES was observed. This could be attributed to the limited
sample size at baseline and the angiographic follow-up.
Regarding to the clinical outcomes, the incidence of MACE
at 6 months was similar in the ADEPT trial (14.0%) and
the ISAR-CABG trial (10.7%), both due mostly to clinically
driven TLR.
Finally, the high MACE rate found in in the literature
and in this study confirms that SVGs are still different from
native coronaries, and may require a different procedural
approach.
Limitations of the study
This study was underpowered to test the study hypothesis,
because of a slower than anticipated enrolment. Therefore
57 patients were included in the study instead of 80, as
planned. The lumen loss in the BMS group was higher than
estimated in the statistical design: a larger number of pa-
tients than estimated may have been needed. However, the
findings of this study remain concordant with similar stud-
ies. Larger randomised studies comparing self-expanding
stents with balloon-expanding stents are needed to further
determine differences and optimise clinical practice. Fur-
thermore, this study was conducted with the older gener-
ation of paclitaxel-eluting STENTYS self-apposing stents.
Late catch-up and thrombosis of paclitaxel-eluting stents
have been reported. In the meantime, the current genera-
tion of the STENTYS self-apposing stent (STENTYS Xpo-
sition) has been modified to elute sirolimus. Also, opti-
mal positioning was challenging with the older generation
STENTYS stent because of shortening of the stent at de-
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Table 4 The characteristics of the four RCTs: ISAR-CABG, SOS, BASKET and RRISC
Trial No of pa-
tients
DES/BMS
TVR Myocardial
infarction
All-cause mortality Type of DES Follow-up
ISAR-CABG [15] 303/307 7%/13%
p = 0.01
4%/6%
p = 0.27
5%/5%
p = 0.83
PES OR permanent
SES OR biodegrad-
able SES
12 months
SOS [16, 17] 41/39 15%/31%
p = 0.08
15%/31%
p = 0.10
12%/5%
p = 0.27
PES 24 months
BASKET [18] 34/13 18%/46%
p = 0.045
6%/0%
p = 1.00
3%/15%
p = 0.18
PES OR SES 18 months
RRISC [19, 20] 38/37 4.3%/24.5%
p = 0.005
2.6%/0%
p = 0.99
13.2%/29.7%
p = 0.08
SES 6 months
DES drug-eluting stent, BMS bare metal stent, TVR target vessel revascularisation, PES paclitaxel-eluting stent, SES sirolimus-eluting stent
ployment due to retracting an outer sheath which releases
the stent from the distal edge. A novel balloon delivery
system for the STENTYS SES, (the STENTYS Xposition),
was therefore developed to improve accurate stent position-
ing[21].
Conclusion
Treatment of SVGs with STENTYS self-expandable stents
was safe, without showing any difference in outcomes be-
tween BMS vs PES arms. No significant differences were
found in late lumen loss and MACE between STENTYS
BMS and STENTYS PES during the follow-up period. Fur-
ther larger randomised studies are needed to investigate dif-
ferences between the two groups.
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